FDA Permits Expanded Access for Investigational Pancreatic Cancer Drug

FDA Permits Expanded Access for Investigational Pancreatic Cancer Drug

Summary

FDA is announcing that it issued a “safe to proceed” letter to Revolution Medicines, allowing the sponsor to initiate an expanded access treatment protocol ...

Original reporting

Open original source

AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.

Related coverage